Flying Blind on CRA Workload, Time Demands


Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-07-01-2012
Volume 21
Issue 7

Despite their growing role, little benchmark management data, until now, existed on global study monitors.

Study monitors—or clinical research associates (CRAs)—are on the front line of clinical trials. They are the vital link between the project team and professionals conducting the study and recruiting patients. From building and maintaining rapport with investigative site personnel to making sure that study staff are adhering to the protocol; from ensuring data quality and integrity to protecting the safe and ethical treatment of study volunteers, CRA workload and time demands are intense and they are growing.

Kenneth A. Getz

Increasingly complex protocols and the rising volume of internationally disbursed clinical trials among less experienced investigative sites are but a few of the drivers of CRA workload. In addition, recent studies show that the majority of sponsor companies conservatively interpret regulatory guidelines and require their CRAs to conduct 100% source data verification.

Concerns about the unprecedented demands on CRA workload and the possibility of potential lapses in study oversight and clinical data quality and integrity have prompted the FDA to issue draft guidance, and the EMA to issue a reflection paper, promoting a risk-based approach to study monitoring. These concerns, however, lack basic metrics characterizing CRA workload and time utilization. In fact, no benchmarks or standard methods have ever been developed to evaluate CRA work and time demands. Sponsors and CROs are maintaining internal management metrics, but they're flying partially blind without insight from comparisons with external benchmarks.

To address this need, the Tufts Center for the Study of Drug Development (Tufts CSDD) conducted a quantitative assessment to gather metrics on how CRA time is allocated, how workload is apportioned, and to establish baseline data from which to measure the impact of regulatory reforms and new practices.

A working group of 18 mid-sized and large pharmaceutical, biotechnology, and CRO companies participated in the study. These companies distributed an online survey to 11,156 CRAs operating throughout the world. Completed surveys from 3,970 CRAs—nearly all (94%) are employed as full time study monitors—were analyzed. Seven out of 10 respondents (2,763) were CRAs employed by CROs, and pharmaceutical and biotechnology companies employed 26% (1,030) of respondents. Staffing agencies employed the remainder.

A detailed report on this study is available from Tufts CSDD.

Average age and experience

Survey respondents monitored clinical trials across a broad range of therapeutic areas including oncology, cardiovascular, CNS, and endocrine disorders. Most respondents (83%) monitored Phase II and Phase III studies and the remainder focused on Phase I studies.

CRAs have been monitoring clinical trials in their primary therapeutic areas of focus an average of 6.3 years. Wide differences in experience level were observed with US-based, Canadian, and Western European CRAs having the highest average experience—8.6 years, 8.9 years, and 6.5 years respectively. CRAs based in Asia/Pacific, Latin America, and Eastern Europe had significantly lower levels of experience than their peers based in more mature global markets.


CRA workload was measured on a per month basis across several dimensions including:

  • Number of protocols for which patients are actively participating but have not yet completed their last visit

  • Number of "planned" investigative sites for which the study monitor has yet to conduct a site initiation visit

  • Number of "activated" investigative sites for which the CRA has already completed a site initiation visit, and the site is actively screening and enrolling study volunteers

  • Number of active study subjects under CRA oversight

  • Number of site monitoring visits.

For Phase I studies, each month CRAs conduct on average 3.8 site monitoring visits; oversee an average of 2.0 protocols; 2.9 planned and 3.1 activated investigative sites; and 21.3 active study volunteers.

For Phase II-III studies, the average workload per month was 3.5 protocols; 5.8 planned and 8.9 activated investigative sites; and 61.9 active study volunteers. CRAs supporting Phase II-III studies conduct an average of 7.9 site monitoring visits each month.

Regional workload differences were observed, particularly in Phase II-III studies. CRAs based in Canada and Latin America conduct a significantly higher relative number of site monitoring visits per month.

US-based and Western European CRAs monitored a relatively higher average number of activated sites. CRAs in Asia/Pacific had significantly lower workloads across all dimensions.


CRA utilization was measured in hours per month. Study monitor time was allocated across five broad categories:

  • Time traveled to meetings and investigative site monitoring visits

  • Time devoted to administrative tasks such as timesheet completion, expense reporting, travel planning, paperwork filing, letter and e-mail writing, and scheduling appointments

  • Time dedicated to training and professional development

  • Time spent on off-site monitoring activities including preparation for site visits, remote data monitoring; report writing; and follow-up after site visits have been conducted

  • Time spent physically at the investigative site conducting a monitoring visit

Overall, CRAs spend a total of 165 hours each month managing their responsibilities. Four out of every 10 hours (41%) are spent on-site conducting monitoring visits. Approximately 22% of total CRA time—36 hours on average per month—is spent on off-site monitoring activities. Eighteen percent of total CRA time is spent traveling to meetings and monitoring visits. Administrative tasks and training make up the remaining 19% of total CRA time at 22 and nine hours respectively.

CRAs employed by pharmaceutical and biotechnology companies work an average of 14 hours more than do those employed by CROs. Sponsor-employed CRAs spend more time conducting on-site monitoring visits, performing off-site monitoring, and administrative tasks each month. CRAs employed by CROs spent more time traveling each month.

Wide variations in time utilization were observed across geographic regions. North American-based CRAs spend significantly more time performing their responsibilities: US-based CRAs spend 178 hours on average each month; and Canadian CRAs spend 171 hours on average each month. US- and Canada-based CRAs spend the highest relative time conducting on-site monitoring visits every month. US-based CRAs also spend the highest relative amount of time traveling.

CRAs in Western and Eastern Europe spend the least relative average total time per month performing their responsibilities. Asia/Pacific CRAs also spend significantly fewer hours performing on-site monitoring visits than do their North American colleagues. Western European CRAs spend 45% fewer average hours traveling than do their peers based in the United States.

Flying with benchmarks

The Tufts CSDD study provides baseline metrics that managers in pharmaceutical, biotechnology, and CRO companies can use to benchmark the workload and utilization of their study monitors. These metrics show that global CRAs spend 60% of their time conducting on-site monitoring visits and traveling to and from these visits. The results of this study show that North American CRAs work the longest hours and allocate more time to on-site monitoring and travel than do their peers in other regions around the world.

Many factors influence the amount of time that CRAs spend on-site including the volume of source data to review, protocol and recruitment complexity, the number of subjects enrolling in the study and the pace of enrollment, and investigative site experience. It is impossible to determine from this study whether 40% of the time spent in face-to-face interactions, on location, with site personnel is sufficient. Tying this baseline metric to quality and performance measures will serve as a useful benchmark for future comparisons, particularly when changes in on-site monitoring practices including new risk-based monitoring approaches are implemented.

Tracking change

The roles and responsibilities of study monitors are expected to evolve substantially over the next several years due to a number of factors including the adoption of new technology solutions (e.g., electronic health records), the changing global operating environment and infrastructure for conducting clinical trials, and regulatory pressures to move to a risk-based monitoring approach. Pharmaceutical, biotechnology, and CRO companies also face unrelenting pressure to lower clinical development costs and improve efficiency. The baseline metrics from the Tufts CSDD study offer regulators and sponsor and CRO companies the opportunity to quantitatively assess the impact of new reforms and practices on CRA workload and utilization.

Ultimately, more informed CRA management better ensures data quality and integrity, the safe and ethical treatment of study volunteers, protocol adherence, and more successful site performance.

Kenneth A. Getz MBA, is a Senior Research Fellow at the Tufts CSDD and Chairman of CISCRP, both in Boston, MA, email:

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.